Constipation in Emergency Medicine Workup
- Author: Dave A Holson, MD, MBBS, MPH; Chief Editor: Barry E Brenner, MD, PhD, FACEP more...
Laboratory Studies
- Serum chemistry may exclude any metabolic causes of constipation, such as hypokalemia and hypercalcemia.
- Complete blood count (CBC) may reveal any anemia that might be associated with rectal bleeding (gross or occult).
- Thyroid function tests may be helpful with patients suspected of having hypothyroidism.
Imaging Studies
- Plain film of the abdomen (upright and flat) and an upright chest film
- These studies underscore the amount of stool present in a patient's colon. Differentiation of fecal impaction, bowel obstruction, and fecalith is possible.
Large amount of stool throughout the colon.
Large stool mass in hepatic flexure of the colon.
Colon distension secondary to fecal impaction. - Diagnosis of fecaliths is important because of the dreaded complication of stercoral ulcers, which can lead to colonic perforation. Stercoral perforation is a rare but life-threatening surgical emergency of perforation due to pressure necrosis that can lead to peritonitis.
- Diabetic gastropathy, as well as fecal impaction, may be seen in patients with diabetic neuropathy.
- Residual barium (from barium enemas) can be visualized.
- Scleroderma and other connective-tissue diseases may be complicated by motor disturbances that mimic colonic obstruction on plain film.
- Myxedema ileus is a consequence of hypothyroidism.
- These studies underscore the amount of stool present in a patient's colon. Differentiation of fecal impaction, bowel obstruction, and fecalith is possible.
Other Tests
- An extensive workup of the constipated patient is performed on an outpatient basis and usually occurs after approximately 3-6 months of failed medical management.
- Anatomic tests include Gastrografin enema, proctosigmoidoscopy, and colonoscopy.
- Physiologic tests include the following: colonic transit study (which uses radio-opaque markers in patients with suspected slow-transit constipation), defecography (which identifies internal rectal intussusception), and anorectal manometry and surface anal electromyography (which help to confirm pelvic floor dyssynergia or anismus).
Procedures
- Anoscopy: Routinely perform anoscopy on all constipated patients to visualize anal fissures, ulcers, hemorrhoids, and local anorectal malignancy.
- Digital disimpaction: A well-lubricated gloved finger might be required in patients with lower anorectal impactions.
- Warm water enemas: These usually are unpopular among the nursing staff and probably are not necessary within the ED.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. Apr 2006;130(5):1480-91. [Medline].
Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J. Feb 2004;97(2):129-34. [Medline].
Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the United States. Manag Care Interface. Dec 2006;19(12):43-9. [Medline].
Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum. Jan 1989;32(1):1-8. [Medline].
[Guideline] Ternent CA, Bastawrous AL, Morin NA, Ellis CN, Hyman NH, Buie WD. Practice parameters for the evaluation and management of constipation. Dis Colon Rectum. Dec 2007;50(12):2013-22. [Medline]. [Full Text].
Kapoor S. Management of constipation in the elderly: emerging therapeutic strategies. World J Gastroenterol. Sep 7 2008;14(33):5226-7. [Medline]. [Full Text].
Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. May 29 2008;358(22):2344-54. [Medline]. [Full Text].
Camilleri M. Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil. Apr 2005;17(2):157-65. [Medline].
Kraft MD. Emerging pharmacologic options for treating postoperative ileus. Am J Health Syst Pharm. Oct 15 2007;64(20 Suppl 13):S13-20. [Medline].
Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol. Feb 2009;296(2):G295-301. [Medline]. [Full Text].
Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. Jan 2008;103(1):170-7. [Medline].
Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. Apr 2010;55(4):1090-7. [Medline].
Pharmaceutical Business Review. Ironwood Pharma, Forest Labs Present Linaclotide Phase 3 Trial Results. pharmaceutical-business-review.com. Available at http://clinicaltrials.pharmaceutical-business-review.com/news/ironwood_pharma_forest_labs_present_linaclotide_phase_3_trial_results_100504/. Accessed May 4, 2010.
Lembo AJ, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. Mar 2010;138(3):886-95.e1. [Medline].
Johanson JF. Review of the treatment options for chronic constipation. MedGenMed [serial online]. May 2, 2007;9 (2):25-40. Accessed April 26, 2010. Available at http://www.medscape.com/viewarticle/550956.
[Best Evidence] [Guideline] Eoff JC. Optimal treatment of chronic constipation in managed care: review and roundtable discussion. J Manag Care Pharm. Nov 2008;14(9 Suppl A):1-15. [Medline]. [Full Text].
Halligan S, Bartram CI. The radiological investigation of constipation. Clin Radiol. Jul 1995;50(7):429-35. [Medline].
Harari D, Gurwitz JH, Avorn J, Bohn R, Minaker KL. How do older persons define constipation? Implications for therapeutic management. J Gen Intern Med. Jan 1997;12(1):63-6. [Medline]. [Full Text].
Johanson JF, Sonnenberg A, Koch TR. Clinical epidemiology of chronic constipation. J Clin Gastroenterol. Oct 1989;11(5):525-36. [Medline].
Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008;3(2):357-64. [Medline]. [Full Text].
Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008;3(2):357-64. [Medline]. [Full Text].
Lembo A, Camilleri M. Chronic constipation. N Engl J Med. Oct 2 2003;349(14):1360-8. [Medline].
Martin H, Slyk MP, Deymann S, Cornacchione MJ. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia. J Am Med Dir Assoc. Jul-Aug 2003;4(4):183-8. [Medline].
Mezwa DG, Feczko PJ, Bosanko C. Radiologic evaluation of constipation and anorectal disorders. Radiol Clin North Am. Nov 1993;31(6):1375-93. [Medline].
Rantis PC Jr, Vernava AM 3rd, Daniel GL, Longo WE. Chronic constipation--is the work-up worth the cost?. Dis Colon Rectum. Mar 1997;40(3):280-6. [Medline].
Schiller LR. New and emerging treatment options for chronic constipation. Rev Gastroenterol Disord. 2004;4 Suppl 2:S43-51. [Medline].
Shafik A. Constipation. Pathogenesis and management. Drugs. Apr 1993;45(4):528-40. [Medline].
Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum. Jan 1989;32(1):1-8. [Medline].
Velio P, Bassotti G. Chronic idiopathic constipation: pathophysiology and treatment. J Clin Gastroenterol. Apr 1996;22(3):190-6. [Medline].

